SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss Q3 results sparked a sharp, volatile reaction: despite a strong reported quarter, traders focused on higher planned capital spending and delayed capacity and revenue milestones, raising concerns about funding needs and potential dilution. Bulls argued that strong AI-cloud demand, customer prepayments and the longer-term outlook supported the business, while some also blamed broader pressure from Nvidia-related headlines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Nvidia board discussions about potentially removing Jensen Huang, amid allegations involving a company executive and a suspected Chinese spy, have driven concern about leadership continuity and national-security scrutiny. Traders are divided between fearing a CEO transition and further fallout, and viewing the selloff as a buying opportunity because Nvidias AI business remains strong.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas reported Q3 revenue beat and raised outlook are driving attention, with traders highlighting its large backlog and earlier profitability target. Bulls are calling for a short squeeze, while skeptics point to weaker margins, a wider adjusted EBITDA loss, and falling cash reserves.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines stronger-than-expected Q3 results, including positive free cash flow and a record backlog, are driving attention, with traders also citing the companys revenue outlook. Many see the report as a potential turnaround, while skeptics point to ongoing losses, dilution concerns and the stocks history of giving back gains.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the FDAs Nov. 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, with the application now centered on preserving upper-limb function. The recent rally has fueled approval and short-squeeze speculation, while skeptics point to the earlier advisory committee vote and warn that the outcome remains uncertain.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A strong quarterly report and raised outlook sparked a sharp rally, but traders then focused on reports of turmoil around Nvidia CEO Jensen Huang and whether it could affect CoreWeaves ties to Nvidia. Bulls say AI demand and contracted backlog remain intact, while bears point to heavy debt costs and potential dilution as risks that the earnings momentum may not resolve.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention after Q3 results showed sharply higher year-over-year revenue but missed analyst expectations. Traders are split between optimism about its AI-cloud backlog and project financing and concern that contracts have yet to translate into sustained revenue and profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is driving concern about passive-fund selling and weaker institutional demand; traders also point to Bitcoins decline as pressure on the stock. Bearish voices expect further downside, while bulls argue the index news is priced in and Bitcoins direction matters more.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks quarterly results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, and reaffirmed full-year guidance alongside a larger backlog tied to AI data-center power demand. Many see the report as bullish and speculate that high short interest could amplify a move, while others remain cautious about execution and volatile price action.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs quarterly results drew attention, but managements decision to defer 2027 DefenCath revenue guidance amid uncertainty around CMS reimbursement, utilization and Medicare Advantage is the central concern. Traders are weighing that unclear outlook against stronger-than-expected results and the Heron acquisitions potential to diversify revenue, with reactions split between optimism about the broader portfolio and concern about DefenCaths reimbursement outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kenvue Now #267 Largest Company, Surpassing Biogen

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Kenvue Inc (Symbol: KVUE) has taken over the #267 spot from Biogen Inc (Symbol: BIIB), according to The Online Investor.

 Market capitalization is an important data po...

DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.

Stoke Therapeutics to Present at Upcoming Investor Conferences in November

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet...

These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

Biogen beats Q3 estimates, narrows FY2026 EPS outlook, and sees analysts raise price targets to $290; shares dip 0.3% premarket.read more...

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.

Big Day for Econ Data, Hyperscaler Earnings

We have a solid slate of reports today, both of the earnings variety and regarding economic growth.

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3?

Eli Lilly is expanding beyond GLP-1 drugs as neuroscience and immunology therapies fuel growth ahead of Q3 results, with Kisunla, Taltz and newer drugs in focus.

Biogen (BIIB) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Q3 26 Earnings Conference Call At 8:30 AM ET

(RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:30 AM ET on October 28, 2026, to discuss Q3 26 earnings results...

Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +27.18% and +8.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>JPMorgan highlighted litifilimab’s development for cutaneous lupus erythematosus, a condition with no currently approved targeted therapies.</li><li>Last week, UBS raised its Biogen price target to $270 from $240 while maintaining 'Buy', while RBC Capital lowered its target to $256 from $260 and maintained 'Outperform', according to The Fly.</li><li>Biogen is scheduled to report its third-quarter 2026 results on October 28, with analysts expecting earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</li></ul><p>Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.</p><p>According to The Fly, the firm cited an increasingly compelling pipeline catalyst outlook and improved long-term growth prospects as the company approaches several clinical readouts in 2027.</p><p><a href="https://stocktwits.com/symbol/BIIB">Biogen shares</a> were trading 3.2% higher in premarket trading on Monday at $232.95, putting the stock on track to reach its highest level since July 2024, a more than two-year high.</p><h2 class="st-heading-2">What Are The Clinical Catalysts To Watch?</h2><p>JPMorgan highlighted two investigational treatments in Biogen's pipeline: felzartamab for antibody-mediated rejection and litifilimab for cutaneous lupus erythematosus. The firm identified felzartamab as a potential opportunity worth more than $2 billion and noted that no therapies are currently approved for cutaneous lupus erythematosus, according to The Fly.</p><p>Biogen's second-quarter 2026 materials listed Phase 3 readouts for both programs among the clinical milestones expected in 2027.</p><h2 class="st-heading-2">Why JPMorgan Mentioned Leqembi</h2><p>Leqembi is Biogen's Alzheimer's disease treatment, developed in collaboration with Eisai. Biogen reported global in-market sales of $184 million for Leqembi in the second quarter of 2026, up 15% year over year. U.S. in-market sales were $97 million.&nbsp;</p><p>JPMorgan said Biogen was evolving beyond “just a Leqembi story,” referring to the company's broader business and pipeline in its assessment of the stock.</p><h2 class="st-heading-2">What Have Other Analysts Said?</h2><p>JPMorgan’s upgrade follows price-target adjustments from UBS and RBC Capital last week, according to The Fly.</p><p>On Friday, October 9, UBS raised its price target on Biogen to $270 from $240 while maintaining a Buy rating. The adjustment came as part of the firm's Q3 earnings preview for U.S. pharmaceutical and large-cap biotech companies, according to The Fly.</p><p>On Thursday, October 8, RBC Capital lowered its price target to $256 from $260 while maintaining an Outperform rating. In its broader biotech earnings preview, RBC said the quarter was shaping up reasonably well for large-cap companies, helped partly by additional selling days and mid-year price increases.</p><p>RBC added that quarterly performance alone might not fully reverse sentiment toward commercial mid-cap biotech companies, although it “may help restore confidence in select stories,” according to The Fly.</p><h2 class="st-heading-2">When Is Biogen Reporting Q3 2026 Earnings?</h2><p>Biogen is scheduled to report its third-quarter 2026 financial results on Wednesday, October 28, before the market opens.</p><p>Analysts expect earnings of $2.66 per share and revenue of approximately $2.65 billion, according to FiscalAI.&nbsp;</p><h2 class="st-heading-2">How Retail Views BIIB?</h2><p>Retail sentiment on Stocktwits remained ‘neutral,’ while message volume was ‘high’ over the past 24 hours.</p><p>Biogen shares have gained more than 27% year-to-date.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bmnr-stock-gains-with-ethereum-outpacing-bitcoin-after-84-k-bounce/cZxIe9tRBFw"><strong>BMNR Stock Gains With Ethereum Outpacing Bitcoin After $84K Bounce Ahead Of CPI Report This Week</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medical bottles and syringe are seen with Biogen logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Shares of Biogen(BIIB) were in focus on Monday after JPMorgan upgraded the stock to an ‘Overweight’ rating from ‘Neutral’ rating and raised its price target to $300 from $210.

Biogen Is More Than ‘A Leqembi Story,’ Says Analyst – Flags Two Other Drug Candidates That Could Change Its Growth Story

According to The Fly, JPMorgan sees a potential market opportunity of more than $2 billion for Biogen’s felzartamab in antibody-mediated rejection.


Track BIIB stock price, charts, news and real-time market activity on Stocktwits. Join the BIIB message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Biogen Inc stock.

BIIB Stock Price Today - Biogen Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$2.81	--	--	N/A
Q3 '26	$1.98	$2.62	32.09%	BEAT
Q2 '26	$2.94	$3.60	22.49%	BEAT
Q1 '26	$3.08	$3.57	15.77%	BEAT
Q4 '25	$1.63	$1.99	22.45%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BIIB Earnings

Latest Earnings Results: Q3 '26

Historical Earnings